Plain-English translation of NCT07541391 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called CAR T-cells for patients with multiple myeloma that has come back or stopped responding to previous medicines. Doctors will take some of your immune cells, reprogram them in the laboratory to recognize and attack your cancer, and then give them back to you in a single infusion after some preparation chemotherapy. This approach harnesses your own body's immune system to fight the disease.
Multiple myeloma patients who have already tried two or more standard treatments often have very limited options and poor outcomes. This medication represents a new strategy that targets a specific marker on myeloma cells, offering hope for patients who have run out of other choices.
You likely qualify if…
You likely don't qualify if…
You will first undergo a procedure called apheresis, where doctors collect some of your white blood cells from your blood. These cells are then sent to the laboratory to be engineered into the new treatment cells. While you wait for the cells to be ready, you will receive chemotherapy to prepare your body. Once your engineered cells are ready, you will receive a single infusion of the medication, likely as an outpatient or with a brief hospital stay. You will then need close follow-up visits to monitor how well the treatment works and manage any side effects.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Australia